NASDAQ:VBIV - VBI Vaccines Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$3.19 +0.02 (+0.63 %)
(As of 06/21/2018 04:10 AM ET)
Previous Close$3.19
Today's Range$3.10 - $3.2231
52-Week Range$2.82 - $5.10
Volume248,665 shs
Average Volume172,669 shs
Market Capitalization$208.70 million
P/E RatioN/A
Dividend YieldN/A
Beta2.08
VBI Vaccines logoVBI Vaccines Inc., a biopharmaceutical company, develops and sells vaccines to address unmet needs in infectious disease and immuno-oncology in Israel and internationally. The company offers Sci-B-Vac, a third-generation hepatitis B vaccine for adults, children, and newborns; and eVLP, a vaccine platform for the design of enveloped virus-like particle vaccines that closely mimic the target virus. It is also developing congenital cytomegalovirus vaccine candidate for infectious disease; and therapeutic glioblastoma multiforme vaccine candidate for immuno-oncology. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. The company is headquartered in Cambridge, Massachusetts. VBI Vaccines Inc. is a subsidiary of FDS Pharma ASS.

Receive VBIV News and Ratings via Email

Sign-up to receive the latest news and ratings for VBIV and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:VBIV
CUSIPN/A
Phone617-830-3031

Debt

Debt-to-Equity Ratio0.11
Current Ratio3.77
Quick Ratio3.72

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$860,000.00
Price / Sales238.21
Cash FlowN/A
Price / CashN/A
Book Value$1.88 per share
Price / Book1.70

Profitability

EPS (Most Recent Fiscal Year)N/A
Net Income$-38,990,000.00
Net Margins-4,607.13%
Return on Equity-47.54%
Return on Assets-36.98%

Miscellaneous

Employees103
Outstanding Shares64,220,000

VBI Vaccines (NASDAQ:VBIV) Frequently Asked Questions

What is VBI Vaccines' stock symbol?

VBI Vaccines trades on the NASDAQ under the ticker symbol "VBIV."

How were VBI Vaccines' earnings last quarter?

VBI Vaccines (NASDAQ:VBIV) announced its quarterly earnings results on Tuesday, May, 1st. The biopharmaceutical company reported ($0.19) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.16) by $0.03. The biopharmaceutical company earned $0.18 million during the quarter, compared to the consensus estimate of $0.21 million. VBI Vaccines had a negative net margin of 4,607.13% and a negative return on equity of 47.54%. View VBI Vaccines' Earnings History.

What price target have analysts set for VBIV?

3 Wall Street analysts have issued 12 month price objectives for VBI Vaccines' stock. Their predictions range from $10.00 to $13.00. On average, they anticipate VBI Vaccines' share price to reach $11.50 in the next twelve months. View Analyst Ratings for VBI Vaccines.

Who are some of VBI Vaccines' key competitors?

Who are VBI Vaccines' key executives?

VBI Vaccines' management team includes the folowing people:
  • Mr. Jeff R. Baxter, CEO, Pres & Director (Age 57)
  • Dr. David Evander Anderson, Chief Scientific Officer (Age 48)
  • Dr. Francisco Diaz-Mitoma, Chief Medical Officer (Age 63)
  • Ms. Athena Kartsaklis, Sr. VP of Fin., Chief Compliance Officer & Principal Financial Officer (Age 53)
  • Ms. Nell Beattie, Chief Bus. Officer (Age 30)

Has VBI Vaccines been receiving favorable news coverage?

Media coverage about VBIV stock has been trending somewhat positive this week, Accern Sentiment Analysis reports. The research group ranks the sentiment of news coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. VBI Vaccines earned a daily sentiment score of 0.07 on Accern's scale. They also gave media headlines about the biopharmaceutical company an impact score of 45.67 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the next few days.

Who are VBI Vaccines' major shareholders?

VBI Vaccines' stock is owned by a number of of institutional and retail investors. Top institutional investors include Menora Mivtachim Holdings LTD. (4.23%), Cambridge Investment Research Advisors Inc. (2.17%), Sphera Funds Management LTD. (1.04%) and Russell Investments Group Ltd. (0.77%). Company insiders that own VBI Vaccines stock include Francisco Diaz-Mitoma, Jeff Baxter, Life Sciences Maste Perceptive, Opko Health, Inc, Perceptive Advisors Llc and Steven Gillis. View Institutional Ownership Trends for VBI Vaccines.

Which institutional investors are selling VBI Vaccines stock?

VBIV stock was sold by a variety of institutional investors in the last quarter, including Sphera Funds Management LTD. and Cambridge Investment Research Advisors Inc.. View Insider Buying and Selling for VBI Vaccines.

Which institutional investors are buying VBI Vaccines stock?

VBIV stock was acquired by a variety of institutional investors in the last quarter, including Menora Mivtachim Holdings LTD. and Russell Investments Group Ltd.. Company insiders that have bought VBI Vaccines stock in the last two years include Francisco Diaz-Mitoma, Jeff Baxter, Life Sciences Maste Perceptive, Opko Health, Inc, Perceptive Advisors Llc and Steven Gillis. View Insider Buying and Selling for VBI Vaccines.

How do I buy shares of VBI Vaccines?

Shares of VBIV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is VBI Vaccines' stock price today?

One share of VBIV stock can currently be purchased for approximately $3.19.

How big of a company is VBI Vaccines?

VBI Vaccines has a market capitalization of $208.70 million and generates $860,000.00 in revenue each year. VBI Vaccines employs 103 workers across the globe.

How can I contact VBI Vaccines?

VBI Vaccines' mailing address is 222 Third Street Suite 2241, Cambridge MA, 02142. The biopharmaceutical company can be reached via phone at 617-830-3031 or via email at [email protected]


MarketBeat Community Rating for VBI Vaccines (VBIV)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  139 (Vote Outperform)
Underperform Votes:  121 (Vote Underperform)
Total Votes:  260
MarketBeat's community ratings are surveys of what our community members think about VBI Vaccines and other stocks. Vote "Outperform" if you believe VBIV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VBIV will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.